Compare Gilead Sciences, Inc. (GILD) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Uranium Energy Corp — how do they compare? Gilead Sciences, Inc. trades at $133.11 (market cap $163.51B), while Uranium Energy Corp trades at $9.86 (market cap $5.00B). The key difference: Gilead Sciences, Inc. is far larger — about 32.7× Uranium Energy Corp's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| GILD | UEC | |
|---|---|---|
Market Cap | $163.51B | $5.00B |
Sector | Health | Energy |
52-Week High | $155.80 | $20.14 |
52-Week Low | $108.22 | $7.63 |
Enterprise Value | $178.05B | $4.52B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Uranium Energy Corp (UEC) trades at $9.84, down 5.29% today, reflecting ongoing volatility. The stock shows a bearish technical bias with weak fundamentals, including a negative net income margin of -513.24% and no revenue in recent quarters. However, analyst sentiment remains largely positive, with 7 of 8 analysts rating it a Buy, citing strategic positioning in U.S. uranium production and a strong $794 million liquidity cushion.
The outlook hinges on execution of production ramp-ups at key projects like Burke Hollow. While the company's debt-free status and strategic inventory offer upside potential, persistent losses, high valuation multiples, and operational delays present significant risks. Investors should weigh the long-term nuclear energy thesis against near-term financial underperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
